A next-generation compound from Boehringer Ingelheim GmbH and Zealand Pharma A/S hit a range of goals in a study of obesity-linked liver disease, in an early sign of how competitive the drug might be in a rapidly growing weight-loss market.
Source link
Boehringer’s Weight-Loss Challenger Hits Goals in Liver Study
Related Posts
Vista Winds Down Hedge Fund, Citing Dominance of Private Markets
Vista Equity Partners has told investors it’s winding down its hedge fund amid a “structural shift” in markets toward private assets. Source link
T-Mobile Postpones $561 Million Wireless Equipment ABS Offering
T-Mobile US Inc. is postponing its sale of more than $500 million in asset backed securities supported by wireless equipment plans, according to people familiar with the matter. Source link